Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-07. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
== Advances in step-growth polymers == The driving force in designing new polymers is the prospect of replacing other materials of construction, especially metals, by using lightweight and heat-resistant polymers. The advantages of lightweight polymers include high strength and resistance to solvent and other chemicals, contributing to a variety of potential uses, such as electrical and engine parts on automotive and aircraft components, coatings on cookware, coatings and circuit boards for electronic and microelectronic devices, etc. Polymer chains based on aromatic rings are desirable due to high bond strengths and rigid polymer chains. High molecular weight and crosslinking are desirable for the same reason. Strong dipole-dipole interactions, hydrogen bonds, and crystallinity also improve heat resistance. To obtain desired mechanical strength, sufficiently high molecular weights are necessary, however, decreased solubility is a problem. One approach to solve this problem is to introduce of some flexibilizing linkages, such as isopropylidene, C=O, and SO2 into the rigid polymer chain by using an appropriate monomer or comonomer. Another approach involves the synthesis of reactive telechelic oligomers containing functional end-groups capable of reacting with each other; polymerization of the oligomer gives higher molecular weight, referred to as chain extension.
=== EC 1.17.7 With an iron–sulfur protein as acceptor === EC 1.17.7.1: (E)-4-hydroxy-3-methylbut-2-enyl-diphosphate synthase (ferredoxin) EC 1.17.7.2: 7-hydroxymethyl chlorophyll a reductase EC 1.17.7.3: (E)-4-hydroxy-3-methylbut-2-enyl-diphosphate synthase (flavodoxin) EC 1.17.7.4: 4-hydroxy-3-methylbut-2-enyl diphosphate reductase
== Biography == Richardson was born on January 25, 1941, and grew up in Teaneck, New Jersey. Her father was an electrical engineer and her mother was an English teacher. Her parents encouraged an interest in science and she was a member of local astronomy clubs as early as elementary school. She attended Teaneck High School and in 1958 won third place in the Westinghouse Science Talent Search, the most prestigious science fair in the United States, with calculations of the satellite Sputnik's orbit from her own observations. She continued her education intending to study mathematics, astronomy and physics at Swarthmore College. However, Richardson instead graduated Phi Beta Kappa with a bachelor's degree in philosophy and a minor in physics in 1962 before she pursued graduate work in philosophy at Harvard University. Meanwhile, she was able to enroll in plant taxonomy and evolution courses at Harvard that would later contribute to her big-picture approach to studying protein structure. Since Harvard's philosophy focused on modern philosophy instead of Richardson's interest, classical philosophy, Richardson left with her master's degree from Harvard in 1966. Post-graduation, Richardson tried teaching high school, but soon realized that this career path was not for her. She subsequently rejoined the scientific world, working as a technician at Massachusetts Institute of Technology in the same laboratory as her husband, David Richardson, whom she met at Swarthmore College.
=== Brand collaborations === American fashion brand Denim Tears would be the first brand to collaborate with Clipse, unveiling a Let God Sort Em Out-branded T-shirt in June 2024, a whole year before the album's eventual release; this was in celebration of the brand's fifth anniversary. Further brand collaborations remained unknown until the release of "So Be It" on June 18, 2025, where Clipse would unveil an alternate album package and merchandise line, designed by Japanese artist Verdy. Williams's Billionaire Boys Club line would announce an exclusive black T-shirt on June 21. The company made the T-shirt available at their flagship stores from that date forward, with the shirt releasing online on July 11. Pusha T would begin teasing Clipse-branded Adidas Samba shoes on July 7; they were given an early-access release on July 14. A Carhartt collaboration was announced the following day; it was released alongside the album on July 11, featuring jackets, graphic T-shirts, a hoodie and sweatshirt. Another alternate album package, designed by American artist Josh Sperling, was announced on July 15.
Sources: en.wikipedia.org
The National Cancer Institute provides additional information on the health effects from exposure to 131I in fallout, as well as individualized estimates, for those born before 1971, for each of the 3070 counties in the US. The calculations are taken from data collected regarding fallout from the nuclear weapons tests conducted at the Nevada Test Site. On 27 March 2011, the Massachusetts Department of Public Health reported that 131I was detected in very low concentrations in rainwater from samples collected in Massachusetts, and that this likely originated from the Fukushima power plant. Farmers near the plant dumped raw milk, while testing in the United States found 0.8 pico-curies per liter of iodine-131 in a milk sample, but the radiation levels were 5,000 times lower than the FDA's "defined intervention level". The levels were expected to drop relatively quickly
== Aftermath == After returning to France in August 1804, Alexander von Humboldt and Aimé Bonpland arrived in Bordeaux after a swift Atlantic crossing. Their return after six years abroad was marked by the need to adjust to changed circumstances and reintegrate into European life. During quarantine, Humboldt wrote to the Institut National in Paris, informing them of his safe arrival. This news caused surprise, as rumors of his death had circulated in Europe. Humboldt reached Paris in late August, looking healthy and energetic. He was warmly welcomed by friends and family, with accounts noting he appeared unchanged by his long absence. Parisian society celebrated Humboldt as a hero. He was honored at scientific meetings and social gatherings, gaining widespread public attention for his South American explorations. His collections and drawings, exhibited at the Jardin des Plantes, attracted large crowds. Within six weeks, the Institut National held a special meeting where Humboldt presented his scientific results, receiving enthusiastic applause. In mid-October, Humboldt presented the first reports of his journey at a meeting of the Institut National des Sciences et Arts, a French government organisation created in 1795 to promote science, the beaux arts, and literature. The meeting was crowded and highly anticipated. In October of that year, the inaugural exhibition of Humboldt's botanical collection was inaugurated at the Jardin des Plantes, where it met with considerable acclaim.
Additional measures may include extracorporeal shockwave therapy or surgery. Between 4% and 7% of people have heel pain at any given time: about 80% are due to plantar fasciitis. Approximately 10% have the disorder at some point. It becomes more common with age. It is unclear whether one sex is more affected than the other.
Analyses have cast doubt on this claim, but the "race-corrected" eGFR remains the standard." They concluded saying "As long as uncertainty persists about the cause of racial differences in serum creatinine levels, we should favor practices that may alleviate health inequities over those that may exacerbate them." In February 2022, the National Kidney Foundation (NKF) and American Society of Nephrology (ASN)'s Joint Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases recommended use of the 2021 CKD-EPI equation which discontinues using a race modifier. In July 2022 the OPTN Board eliminated race-based calculations for transplant candidate listing across all transplant hospitals in the US.
November 2: Law on the labor of children, underage girls, and women in industrial establishments. November 30: Law on the practice of medicine: midwives are prohibited from prescribing medication, they may administer smallpox vaccines, and during childbirth, they are forbidden from using instruments and must call a physician or health officer in case of complications. 1893
Sources: en.wikipedia.org
Petroleum is used to manufacture a wide variety of materials essential for modern life, and it is estimated that the world consumes about 100 million barrels (16 million cubic metres) each day. Petroleum production played a key role in industrialization and economic development, especially after the Second Industrial Revolution. Some petroleum-rich countries, known as petrostates, gained significant economic and international influence during the latter half of the 20th century due to their control of oil production and trade. Petroleum is a non-renewable natural resource, and its exploitation is damaging to the natural environment, climate system and human health. Extraction, refining and burning of petroleum fuels counteract carbon sinks by releasing large quantities of greenhouse gases back into the Earth's atmosphere, making petroleum one of the major contributors to anthropogenic climate change. Other negative environmental effects, at almost all stages of use, include direct release—such as oil spills—and secondary pollution of air and water sources. Proximity to petroleum deposits, and subsequent access to and pricing of oil have historically fueled both domestic and geopolitical conflicts, state-sanctioned oil wars, diplomatic and trade frictions, energy policy disputes and other resource conflicts. While production is estimated to reach peak oil before 2035, global economic focus on climate change mitigation in the transition to renewable energy sources and increased electrification will greatly reduce dependency on petroleum.
The establishment of permanent boundaries between what later became Lower Saxony and Westphalia began in the 12th century. In 1260, in a treaty between the Archbishopric of Cologne and the Duchy of Brunswick-Lüneburg the lands claimed by the two territories were separated from each other. The border ran along the Weser to a point north of Nienburg. The northern part of the Weser-Ems region was placed under the rule of Brunswick-Lüneburg. The word Niedersachsen was first used before 1300 in a Dutch rhyming chronicle (Reimchronik). From the 14th century it referred to the Duchy of Saxe-Lauenburg (as opposed to Saxe-Wittenberg). On the creation of the imperial circles in 1500, a Lower Saxon Circle was distinguished from a Lower Rhenish–Westphalian Circle. The latter included the following territories that, in whole or in part, belong today to the state of Lower Saxony: the Bishopric of Osnabrück, the Bishopric of Münster, the County of Bentheim, the County of Hoya, the Principality of East Frisia, the Principality of Verden, the County of Diepholz, the County of Oldenburg, the County of Schaumburg and the County of Spiegelberg. At the same time a distinction was made with the eastern part of the old Saxon lands from the central German principalities later called Upper Saxony for dynastic reasons. The close historical links between the domains of the Lower Saxon Circle now in modern Lower Saxony survived for centuries especially from a dynastic point of view.
Another common example is the reaction of a primary amine or secondary amine with a carboxylic acid or with a carboxylic acid derivative to form an amide. This reaction is widely used, especially in the synthesis of peptides. On the simple addition of an amine to a carboxylic acid, a salt of the organic acid and base is obtained. To overcome this, the carboxylic acid first needs to be "activated". This is usually done by converting the acid into a more reactive derivative (i.e. anhydride, acid halide) or by using a coupling agent. In some cases, high temperatures (>200 °C) can overcome salt formation by driving off water, without the need for "activation" of the carboxyl group. The downside to this simple reaction is that the compounds may decompose at these elevated temperatures. The carboxylic acid derivatives can be esters, anhydrides, acid halides or any other activated species. The choice of activated carboxyl group or coupling agent can be very important in peptide synthesis, as using the wrong one can lead to racemization.
{\displaystyle \mathrm {^{238}_{\ 92}U\ \xrightarrow {(n,\gamma )} \ _{\ 92}^{239}U\ {\xrightarrow[{23.5\ min}]{\beta ^{-}}}\ _{\ 93}^{239}Np\ {\xrightarrow[{2.3565\ d}]{\beta ^{-}}}\ _{\ 94}^{239}Pu\ \xrightarrow {2~(n,\gamma )} \ _{\ 94}^{241}Pu\ {\xrightarrow[{14.35\ yr}]{\beta ^{-}}}\ _{\ 95}^{241}Am} }
=== Mechanism of action === Insulin degludec is an ultra-long acting insulin that, unlike insulin glargine, is active at a physiologic pH. The addition of hexadecanedioic acid via an amide linkage to lysine at the B29 position allows for the formation of multi-hexamers in subcutaneous tissues. This allows for the formation of a subcutaneous depot that results in slow insulin release into the systemic circulation.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.